CLEARPOINT NEURO INC (CLPT) Stock Fundamental Analysis

NASDAQ:CLPT • US18507C1036

9.405 USD
-3.17 (-25.18%)
Last: Mar 2, 2026, 10:02 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CLPT. CLPT was compared to 184 industry peers in the Health Care Equipment & Supplies industry. CLPT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CLPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CLPT had negative earnings in the past year.
  • CLPT had a negative operating cash flow in the past year.
  • In the past 5 years CLPT always reported negative net income.
  • In the past 5 years CLPT always reported negative operating cash flow.
CLPT Yearly Net Income VS EBIT VS OCF VS FCFCLPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • With a Return On Assets value of -38.34%, CLPT is not doing good in the industry: 63.04% of the companies in the same industry are doing better.
  • With a Return On Equity value of -145.77%, CLPT is not doing good in the industry: 67.93% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -38.34%
ROE -145.77%
ROIC N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
CLPT Yearly ROA, ROE, ROICCLPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

  • CLPT has a better Gross Margin (61.31%) than 64.67% of its industry peers.
  • In the last couple of years the Gross Margin of CLPT has declined.
  • The Profit Margin and Operating Margin are not available for CLPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
CLPT Yearly Profit, Operating, Gross MarginsCLPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CLPT has more shares outstanding
  • CLPT has more shares outstanding than it did 5 years ago.
  • CLPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLPT Yearly Shares OutstandingCLPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CLPT Yearly Total Debt VS Total AssetsCLPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of 0.38, we must say that CLPT is in the distress zone and has some risk of bankruptcy.
  • CLPT has a Altman-Z score (0.38) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.84 is on the high side and indicates that CLPT has dependencies on debt financing.
  • The Debt to Equity ratio of CLPT (1.84) is worse than 80.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.84
Debt/FCF N/A
Altman-Z 0.38
ROIC/WACCN/A
WACC9.97%
CLPT Yearly LT Debt VS Equity VS FCFCLPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • CLPT has a Current Ratio of 6.37. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 6.37, CLPT belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.
  • A Quick Ratio of 5.56 indicates that CLPT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.56, CLPT belongs to the top of the industry, outperforming 84.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.37
Quick Ratio 5.56
CLPT Yearly Current Assets VS Current LiabilitesCLPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • CLPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.74%.
  • CLPT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.83%.
  • CLPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.85% yearly.
EPS 1Y (TTM)-21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)12.83%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%9.1%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.12% on average over the next years.
  • Based on estimates for the next years, CLPT will show a very strong growth in Revenue. The Revenue will grow by 32.35% on average per year.
EPS Next Y-20.94%
EPS Next 2Y-8.31%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue Next Year14.96%
Revenue Next 2Y32.03%
Revenue Next 3Y32.35%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLPT Yearly Revenue VS EstimatesCLPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 2031 2032 50M 100M 150M 200M
CLPT Yearly EPS VS EstimatesCLPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CLPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLPT Price Earnings VS Forward Price EarningsCLPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLPT Per share dataCLPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.31%
EPS Next 3Y3.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CLPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLEARPOINT NEURO INC

NASDAQ:CLPT (3/2/2026, 10:02:08 AM)

9.405

-3.17 (-25.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners40%
Inst Owner Change11.27%
Ins Owners4.98%
Ins Owner Change0.01%
Market Cap279.80M
Revenue(TTM)34.33M
Net Income(TTM)-23.14M
Analysts82.5
Price Target28.56 (203.67%)
Short Float %12.12%
Short Ratio4.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.94%
Min EPS beat(2)-2.94%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-15.18%
Min EPS beat(4)-34.8%
Max EPS beat(4)-2.94%
EPS beat(8)3
Avg EPS beat(8)-2.06%
EPS beat(12)5
Avg EPS beat(12)-4.56%
EPS beat(16)8
Avg EPS beat(16)-0.96%
Revenue beat(2)0
Avg Revenue beat(2)-5.65%
Min Revenue beat(2)-9.51%
Max Revenue beat(2)-1.8%
Revenue beat(4)1
Avg Revenue beat(4)-4.32%
Min Revenue beat(4)-9.51%
Max Revenue beat(4)1.45%
Revenue beat(8)5
Avg Revenue beat(8)-0.07%
Revenue beat(12)6
Avg Revenue beat(12)-1.31%
Revenue beat(16)8
Avg Revenue beat(16)-0.41%
PT rev (1m)-3.45%
PT rev (3m)-3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.15
P/FCF N/A
P/OCF N/A
P/B 17.63
P/tB 17.63
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS1.15
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.34%
ROE -145.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.31%
FCFM N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
F-Score4
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.43%
Cap/Sales 2.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.37
Quick Ratio 5.56
Altman-Z 0.38
F-Score4
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)185.37%
Cap/Sales(3y)3.62%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-20.94%
EPS Next 2Y-8.31%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue 1Y (TTM)12.83%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%9.1%
Revenue Next Year14.96%
Revenue Next 2Y32.03%
Revenue Next 3Y32.35%
Revenue Next 5YN/A
EBIT growth 1Y-20.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.42%
EBIT Next 3Y25.55%
EBIT Next 5YN/A
FCF growth 1Y17.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.21%
OCF growth 3YN/A
OCF growth 5YN/A

CLEARPOINT NEURO INC / CLPT FAQ

What is the fundamental rating for CLPT stock?

ChartMill assigns a fundamental rating of 3 / 10 to CLPT.


What is the valuation status of CLEARPOINT NEURO INC (CLPT) stock?

ChartMill assigns a valuation rating of 0 / 10 to CLEARPOINT NEURO INC (CLPT). This can be considered as Overvalued.


What is the profitability of CLPT stock?

CLEARPOINT NEURO INC (CLPT) has a profitability rating of 1 / 10.


What is the financial health of CLEARPOINT NEURO INC (CLPT) stock?

The financial health rating of CLEARPOINT NEURO INC (CLPT) is 4 / 10.